Fosun Pharma selects Medidata’s unified platform for clinical development in China.
Medidata, a global provider of cloud-based technology and data analytics for clinical research, announced an enterprise agreement with the Chinese healthcare group Shanghai Fosun Pharmaceutical Co., Ltd.’s subsidiary Shanghai Fosun Pharmaceutical Development Co., Ltd. Fosun Pharma has adopted the Medidata Clinical Cloud platform to improve data management capabilities and bring operational efficiencies to its clinical studies in China.
Fosun Pharma is implementing Medidata Rave, a unified EDC and CDMS solution for capturing, managing and reporting patient data, across its generics development pipeline, accelerating treatments in such therapeutic areas as cardiovascular, oncology, anti-infection, and central nervous system (CNS). The Chinese clinical R&D company is also leveraging Rave Study Design and Build Essentials (SDBE) training.
Taught on RaveX—the latest version of Rave—SDBE will equip Fosun Pharma’s study teams with the fundamentals required to develop and update electronic Case Report Forms (eCRFs), ultimately optimizing study implementation and ensuring trial timelines are met.
“We are proud to be Fosun Pharma’s cloud-based, clinical technology platform of choice and a key addition to its roster of partners,” said Edwin Ng, Medidata’s vice president of field operations, APeJ (Asia Pacific except Japan). “We look forward to powering Fosun Pharma’s clinical studies with Medidata’s flexible, cutting-edge technology as they strive to become a first-class enterprise in the global healthcare market and a key player in the bioequivalence space.”
(Source: Business Wire)
